Forge Therapeutics, Inc.
Zachary Zimmerman, Ph.D., CEO & co-founder brings over 15 years of biotechnology business and leadership experience to Forge with prior positions at Arcturus Therapeutics (NASDAQ:ARCT), Regulus Therapeutics (NASDAQ:RGLS), Alnylam Pharmaceuticals (NASDAQ:ALNY), and 454 Life Sciences (acquired by Roche). He has successfully driven company growth through strategic alliances, financings, and non-dilutive grant awards. Growing up in a conservative Pennsylvania farm town did not prevent him from seeing the broader picture, having the vision to make a difference and taking risks to get there. In initiating this journey, following college graduation, he promptly drove across country to San Diego to start his scientific career at The Scripps Research Institute. Zak received a BS in Molecular & Cellular Biology from West Chester University, earned a Ph.D. in Molecular, Cellular & Developmental Biology from University of California, Santa Cruz, and was a Post-doctoral Fellow in Oncology at the Stanford University School of Medicine.